Carcinoid Tumors
September 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review.
Authors:Isenberg-Grzeda E, MacGregor M, Bergel A, Eagle S, Espi Forcen F, Mehta R, Matsoukas K, Wills J, Reidy-Lagunes D, Alici Y
Institution:Department of Psychiatry, Sunnybrook Health Sciences Center, University of Toronto, 2075 Bayview Avenue, Toronto, M4N3M5, Ontario, Canada. Electronic address: elie.isenberggrzeda@sunnybrook.ca.; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10065, NY, USA. Electronic address: macgregorm@mskcc.org.; Long Island Jewish Medical Center, Department of Emergency Psychiatry, 270-05 76th Ave, Glen Oaks, 11004, NY, USA. Electronic address: abergel@northwell.edu.; Department of Psychiatry, Stony Brook University Medical Center, HSC, T10-020, Stony Brook, 11794-8101, NY, USA. Electronic address: Stacy.eagle@gmail.com.; Department of Psychiatry, Rush University Medical Centerm, 1653 W Harrison, Chicago, 60612, IL, USA. Electronic address: fespiforcen@gmail.com.
Journal:Eur J Surg Oncol. 2018 Jun;44(6):744-749. doi: 10.1016/j.ejso.2018.03.010. Epub 2018 Mar 21.

2:Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.
Authors:Tapia Rico G, Li M, Pavlakis N, Cehic G, Price TJ
Institution:Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia. South Wales, Australia. South Wales, Australia. Australia, Australia. Australia, Australia; University of Adelaide, Adelaide, South Australia, Australia. Electronic address: Timothy.Price@sa.gov.au.
Journal:Cancer Treat Rev. 2018 May;66:1-6. doi: 10.1016/j.ctrv.2018.03.002. Epub 2018 Mar 16.

3:Endobronchial carcinoid tumor: Radiological findings of a clinical case.
Authors:Queiroz RM, Santana DBF, Nastri Filho R, Landell GAM, Felix PR, Valentin MVN
Institution:Department of Radiology and Medical Imaging, Documenta - Hospital Sao Francisco, Ribeirao Preto, SP, Brazil.; Department of Anatomical Pathology, Cytopathology and Histology; Anatomical Pathology and Cytopathology Unit, Prof. Dr. Humberto de Queiroz Menezes, Ribeirao Preto, SP, Brazil.
Journal:Rev Assoc Med Bras (1992). 2018 Jan;64(1):15-18. doi: 10.1590/1806-9282.64.01.15.

4:Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
Authors:Brizzi MP, La Salvia A, Tampellini M, Sonetto C, Volante M, Scagliotti GV
Institution:Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy. mariapia.brizzi@email.it.; Department of Medical Oncology and Pathology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy.
Journal:BMC Cancer. 2018 Mar 20;18(1):311. doi: 10.1186/s12885-018-4205-0.

5:LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAIVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Authors:Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI
Journal:Endocr Pract. 2018 Mar;24(3):243-255. doi: 10.4158/EP172000.OR.

6:Carcinoid Heart Disease: Early Outcomes after Surgical Valve Replacement in Nine Patients.
Authors:Mujtaba SS, Clark S
Institution:Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom. United Kingdom.
Journal:Heart Surg Forum. 2018 Feb 16;21(1):E040-E043.

7:Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
Authors:Lewis AR, Wang X, Magdalani L, D'Arienzo P, Bashir C, Mansoor W, Hubner R, Valle JW, McNamara MG
Institution:Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom. 4BX, United Kingdom. 4BX, United Kingdom. M20 4BX, United Kingdom. 4BX, United Kingdom. 4BX, United Kingdom. 4BX, United Kingdom. 4BX, United Kingdom. mairead.mcnamara@christie.nhs.uk.
Journal:World J Gastroenterol. 2018 Feb 14;24(6):671-679. doi: 10.3748/wjg.v24.i6.671.

8:Kidney carcinoid tumor: Histological, immunohistochemical and ultrastructural features.
Authors:Gu X, Cheng M, Herrera GA
Institution:a Department of Pathology , Louisianan State University Health Science Center-Shreveport , Shreveport , LA , USA. Center-Shreveport , Shreveport , LA , USA. Center-Shreveport , Shreveport , LA , USA.
Journal:Ultrastruct Pathol. 2018 Jan-Feb;42(1):18-22. doi: 10.1080/01913123.2017.1388321. Epub 2017 Dec 1.

9:Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
Authors:Joish VN, Frech F, Lapuerta P
Institution:a Lexicon Pharmaceuticals, Inc. , Basking Ridge , NJ , USA.
Journal:J Med Econ. 2018 Feb;21(2):182-188. doi: 10.1080/13696998.2017.1387120. Epub 2017 Oct 9.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 20% Discount


Medifocus Guidebook on Carcinoid Tumors

Updated: June 29, 2018
211 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CT93294810

Coupon Expires: January 14, 2019



What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
P.T.
Newcastle, England


"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
F.B.
Nanaimo, British Columbia


"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
J.P.F.
Agoura Hills, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.